- Research Article
- Open Access
Selective Inhibition of the Human tie-1 Promoter with Triplex-Forming Oligonucleotides Targeted to Ets Binding Sites
Molecular Medicine volume 12, pages8–16(2006)
The Tie receptors (Tie-1 and Tie-2/Tek) are essential for angiogenesis and vascular remodeling/integrity. Tie receptors are up-regulated in tumor-associated endothelium, and their inhibition disrupts angiogenesis and can prevent tumor growth as a consequence. To investigate the potential of anti-gene approaches to inhibit tie gene expression for anti-angiogenic therapy, we have examined triple-helical (triplex) DNA formation at 2 tandem Ets transcription factor binding motifs (designated E-1 and E-2) in the human tie-1 promoter. Various tie-1 promoter deletion/mutation luciferase reporter constructs were generated and transfected into endothelial cells to examine the relative activities of E-1 and E-2. The binding of antiparallel and parallel (control) purine motif oligonucleotides (21–22 bp) targeted to E-1 and E-2 was assessed by plasmid DNA fragment binding and electrophoretic mobility shift assays. Triplex-forming oligonucleotides were incubated with tie-1 reporter constructs and transfected into endothelial cells to determine their activity. The Ets binding motifs in the E-1 sequence were essential for human tie-1 promoter activity in endothelial cells, whereas the deletion of E-2 had no effect. Antiparallel purine motif oligonucleotides targeted at E-1 or E-2 selectively formed strong triplex DNA (Kd ∼10−7 M) at 37 °C. Transfection of tie-1 reporter constructs with triplex DNA at E-1, but not E-2, specifically inhibited tie-1 promoter activity by up to 75% compared with control oligonucleotides in endothelial cells. As similar multiple Ets binding sites are important for the regulation of several endothelial-restricted genes, this approach may have broad therapeutic potential for cancer and other pathologies involving endothelial proliferation/dysfunction.
Tumor growth and the development of hematologic metastases depend on angiogenesis, and the inhibition of this process represents a target for therapy (1). Several endothelial receptor tyrosine kinases (RTKs) play key roles in coordinating vascular proliferation, differentiation, and maintenance/integrity (2,3). These include the vascular endothelial growth factor (VEGF) family of receptors (Flt-1, Flt-4, and KDR/Flk-1) and Tie (Tie-1 and Tie-2/Tek) RTKs (2,3). The Tie receptors are essential for embryonic development, and targeted disruption of the tie genes in mice highlights their importance in angiogenesis and vascular remodeling (4). The angiopoietins (Ang-1 through -4) were identified as ligands for Tie-2 (3). Tie-1 was recently shown to bind Ang-1 and Ang-4 and increase its association with Tie-2 in endothelial cells (5). Proteolytic cleavage of the Tie-1 ectodomain following protein kinase C activation produces a signaling-competent membrane-bound truncated Tie-1 receptor (6). As with Tie-2, the activation of Tie-1 signaling has been reported to promote endothelial cell survival through the phosphoinositol-3-kinase/Akt pathway (7).
In the adult, Tie-1 and Tie-2 are upregulated in endothelium during both physiological and pathological angiogenesis (3,8). Increased Tie receptor expression has been reported in diabetic retinopathy (9), psoriasis (10), and arthritis (11), in the vasculature of human tumors including brain and breast cancers, and in melanoma metastases (3,8,12–16). The soluble extracellular domain of Tie-2 was reported to act in a dominant-negative manner to block tumor-stimulated angiogenesis in the rat cornea and subcutaneous window chamber models (17). Moreover, when delivered systemically, an adenovirus expressing soluble Tie-2 inhibited the growth of primary murine tumors and their metastases (18). Similarly, sTie-1 or anti-Tie-1 antibodies have been shown to inhibit the growth of tumors by disrupting the tumor neovasculature.
Various therapeutic approaches are being investigated to inhibit pathological angiogenesis, including the use of blocking antibodies, small molecule inhibitors, antisense oligonucleotides, and ribozymes (1). A novel alternative strategy is to employ anti-gene approaches to inhibit the expression of angiogenesis-associated genes. To test this paradigm, we are using triple helical (triplex) DNA formation, which relies on the sequence-specific binding of oligonucleotides to duplex DNA (19,20), to validate targets in the endothelial-restricted RTK genes. The ideal triplex DNA target is a homopurine-homopyrimidine sequence that allows the triplex-forming oligonucleotide (TFO) to bind in the major groove of double-stranded DNA, forming Hoogsteen hydrogen bonds with the purine strand (reviewed in 21–23). Triplex DNA formation represents a promising approach to selectively inhibit gene expression. It offers potential advantages over the use of antisense oligonucleotides and ribozymes, as generally only two sequences (alleles) need to be blocked per cell to prevent the generation of all RNA species arising from the target gene (21,22). TFO can be directed to inhibit gene expression by competing with the binding of activating transcription factors to regulatory sites or by disrupting transcriptional elongation (21–32). Advances in this approach have been achieved through the development of oligonucleotide analogs such as N3′ → P5′ phosphoramidates (28), peptide nucleic acid (PNA) (33), and 2′-aminoethoxy-substituted riboses (30) that are resistant to intra- and extracellular nucleases and form strong DNA triplexes (21–23). Whereas the close association of condensed DNA with chromatin can serve as a barrier to DNA triplex formation, this does not appear to present a problem when targeting transcriptionally active regions of DNA (21). Indeed, triplex DNA formation has been successfully targeted to inhibit endogenous gene expression (28). The recent demonstration of triplex-mediated gene modification in a murine model represents a major step toward the use of TFO for gene-based therapies (34). In addition, the current development of novel sequence-specific DNA binding agents (35) may provide alternative agents for the clinical application of anti-gene approaches.
We have identified several potential duplex target sequences in the 5′ regulatory regions of the tie genes (36,37), including three conserved sequences that encode multiple Ets transcription factor core (5′-GGAA/T-3′) DNA binding motifs (38,39). Members of the Ets family of transcription factors are key regulators of many genes associated with differentiation and tissue-specific and homeostatic processes, including angiogenesis (38–45). In this study, we demonstrate that two near-perfect homopurine-homopyrimidine sequences (E-1 and E-2) containing tandem Ets binding sites in the human tie-1 promoter represent good targets for triplex DNA formation with purine motif TFO. By promoter-reporter analysis, we demonstrate that one of these sequences (E-1) is essential for tie-1 promoter activity in cultured endothelial cells, and the selective formation of DNA triplex at the E-1 site leads to significant inhibition of tie-1 promoter activity in endothelial cells.
Materials and Methods
Oligonucleotides synthesized with phosphodiester and phosphorothioate linkages and HPLC-purified were purchased from MWG-Biotech (Germany). The sequences of the antiparallel oligonucleotides, T1-ap and T2-ap targeted to E-1 and E-2, respectively, control parallel oligonucleotides (T1-P and T2-P), and together with parallel pyrimidine motif oligonucleotide, T1(C/T)-P, are shown in Figure 1. The duplex sequences used for electrophoretic mobility shift assays (EMSAs) consist of the E-1 (21 bp) and E-2 (22 bp) near homopurine-homopyrimidine targets with three additional base pairs of the tie-1 flanking sequences at each end (Figure 1).
Generation of tie-1 luciferase reporter constructs
The human tie-1 (∼830 bp) gene promoter (37) was cloned into the pGL3 basic luciferase reporter vector (Promega, WI, USA) (ptie-1luc) as described previously (36). In addition, we cloned a larger 880-bp fragment of the human tie-1 promoter using an alternative 3′ PCR primer (5′-TAC TCC AGA GGC CGA CCC AGG CCA G-3′) under the conditions described previously (36). ptie-1luc (830 bp) 5′ deletion constructs were generated using the Erase-a-base system according to the manufacturer’s instructions (Promega). Briefly, ptie-1luc was subjected to progressive exonuclease-III digestion, blunt ended, religated, and sequenced. Additional 5′ deletions were generated by PCR using ptie-1luc as a template. Specific ptie-1luc Ets binding site mutants were produced by overlap PCR using pfu DNA polymerase (Stratagene, Amsterdam, Netherlands) under the following conditions: 94 °C for 30 s, 60 °C for 1 min, and 76 °C for 3 min for 30 cycles. Mutations were introduced into each of the two Ets binding motifs in E-1 (see Figure 2B) by PCR using the following primers (mut-1 sense 5′-AGC CAC CTC ATT AGC TCT TCC TCC CCA-3′, mut-1 antisense 5′-TGG GGA GGA AGA GCT AAT GAG GTG GCT-3′; and mut-2 sense 5′-AGC CAC CTC ATT TCC TCT AGC TCC CCA-3′, mut-2 antisense 5′-TGG GGA GCT AGA GGA AAT GAG GTG GCT-3′) in combination with primers flanking the tie-1 promoter sequence described previously (36). Mutant E-1 tie-1 PCR products were gel-purified and cloned into pCR-BLUNT (Invitrogen-BV, Netherlands), restriction-digested with SacI and XbaI, and subcloned into the SacI and NheI sites of pGL-3 basic. All DNA plasmids were prepared using Qiagen maxi-prep columns (Qiagen, Sussex, UK) and re-suspended in sterile deionized water.
Plasmid DNA binding assay
Plasmid DNA binding assays were performed essentially as described by Vasquez et al. (46). Briefly, TFO (8 pM) was labeled with 10 µCi [γ32P]dATP (Amersham Pharmacia Biotech UK, Bucks, UK) using 10 U T4-polynucleotide kinase (New England Biolabs, Boston, MA, USA) in a total volume of 10 µL and purified on Chromaspin + STE-10 columns (Clontech, Basingstoke, UK). The ptie-1luc plasmid was restriction-digested with SmaI and AccI (New England Biolabs), phenol-extracted, ethanol-precipitated, and resuspended in deionized water. The digested plasmid DNA (∼1 µg) was incubated with radiolabeled TFO (∼0.2 pM) in 10 µL binding buffer (10 mM Tris-HCl, pH 7.6, containing 10 mM MgCl2 and 10% sucrose) at 37 °C for 16–18 h. Loading buffer (10% Ficoll and 0.1% bromophenol blue) was added (2 µL), and the samples were separated immediately on 1% agarose gels containing ethidium bromide (EtBr) in running buffer (90 mM Tris-Borate buffer, pH 8.0, containing 10 mM MgCl2) at 65 V for 5 h. The DNA was visualized under UV light, and the gels were dried under vacuum at 80 °C on Hybond-N membrane (Amersham Pharmacia Biotech UK) and exposed to film.
Electrophoretic mobility shift assays
For EMSAs, we used oligonucleotides encoding the duplex target sites corresponding to E-1 and E-2 (see Figure 1). The pyrimidine-rich oligonucleotides were labeled with [γ32P]dATP, purified as described above, and annealed with a 1.5-fold excess of the complementary purine-rich oligonucleotide at 95 °C for 10 min and allowed to cool slowly to room temperature. Radiolabeled duplex (2 × 10−9 to 10 × 10−9 M) was incubated with increasing quantities of TFO (0.01 to 500 pmol) in a total volume of 10 binding buffer for 16 to 18 h at 37 °C. Loading buffer (2 µL) was added, and the samples were separated immediately on 6% nondenaturing polyacrylamide gels in running buffer at 100 V for ∼ 2–4 h, dried under vacuum at 80 °C, and exposed to film. The intensity of the bands on the autoradiographs was determined by scanning densitometry (Image-Pro Plus; Media Cybernetics, MD, USA). The dissociation constant (Kd) was estimated by determining the fraction of triplex DNA at each concentration of TFO and calculating the midpoint of the titration when the intensities of the target duplex and triplex bands were equivalent.
Endothelial cell transfection and dual luciferase assays
Bovine aortic endothelial cells (BAECs) were maintained in Dulbecco’s modified Eagle’s medium supplemented with 10% iron-supplemented calf serum, 25 mM l-glutamine, 100 U/mL penicillin, and 100 µg/mL streptomycin sulfate (Sigma). Luciferase reporter constructs were transfected into BAECs at 50% to 60% confluence on 6-well culture dishes using ExGen 500 (Euromedex, France) as described previously (36). Briefly, ExGen 500 (10 µL) was mixed with 2 µg ptie-1luc or SV40 promoter control reporter plasmid (pSV40luc) (Promega) and 8 ng of the CMV-driven Renilla luciferase plasmid (pRL-CMV) in a total volume of 100 µL serum-free RPMI 1640 for 20 min. The cells were incubated with the transfection mixture in a total volume of 1 mL full growth medium at 37 °C. After 6 h, the medium was replaced and the cells incubated for a further 72 h and harvested and the luciferase activity was determined using the Dual Luciferase Assay (Promega) as described previously (36). To examine the activity of TFO on tie-1 promoter activity, various concentrations of TFO and control oligonucleotides were incubated with ptie-1luc or pSV40luc in a total volume of 10 µL binding buffer for 16 to 18 h at 37 °C. Before transfection, these samples were then mixed with 8 ng of pRL-CMV and ExGen 500 (10 µL) in a final volume of 100 µL RPMI 1640 serum-free medium, incubated for 20 min at room temperature, and added to BAECs as described above. Results obtained from duplicate samples were normalized to pRL-CMV activity.
Selection of triplex target sites in the human tie-1 promoter and design of TFOs
Based on our recent characterization of the human tie promoters (36) (P.W.H., unpublished data), we have identified several purine-rich potential triplex DNA target sites in these genes. We selected two sites (E-1 and E-2) in the human tie-1 promoter sequence (37) comprising conserved tandem Ets binding sites as targets for our initial investigations (Figure 1). The E-1 homopurine-homopyrimidine sequence is interrupted by a single T:A inversion and located between 756 and 796 bp; the E-2 sequence containing one G:C inversion lies between 505 and 526 bp of the human tie-1 promoter sequence (37) (GenBank accession no. S79347).
Triplex DNA formation has been described using three oligonucleotide motifs (21,22). Pyrimidine motif (C/T) TFOs bind in a parallel orientation to the purine strand of the target duplex to form C+*G:C (TFO*homopurine:homopyrimidine) and T*AT triplets and require low pH to facilitate the protonation of cytosine bases, whereas purine (G/A) motif TFOs bind in antiparallel orientation to the purine strand of the target duplex forming G*G:C and A*A:T triplets. Mixed (G/T) TFOs may bind in either orientation forming G*G:C and T*AT triplets. We used purine motif TFOs in preference to pyrimidine and mixed motif TFOs, as they form DNA triplex at neutral pH, and as T residues may promote guanine quartet formation by providing the points for stable hairpins in G/T TFOs, respectively (47). We designed specific antiparallel G/A motif oligonucleotides against E-1 and E-2 (Figure 1) using standard rules of triplex DNA formation (21,22). To minimize the destabilizing effect of the G:C to C:G inversion in E-2, we used thymine in T2-ap, as it is reported to weakly associate with C:G inversions (T*C:G) in purine motif TFOs (20,48). However, there is no natural base that will accommodate a T:A inversion in the purine motif, so adenine was used in T1-ap in preference to guanine, as runs of contiguous guanines promote self-association and the formation of multimers (20). Oligonucleotides (T1-P and T2-P) were synthesized in parallel orientation to the purine-rich strand of E-1 and E-2 as controls (Figure 1). To improve the resistance of TFOs to intracellular and extracellular nucleases, we also generated oligonucleotides with phosphorothioate linkages (21,22). As fully phosphorothioate-linked oligonucleotides have been reported to exhibit reduced target specificity and triplex DNA formation (22,49), oligonucleotides were synthesized with phosphorothioate linkages substituted for the last three phosphodiester bonds at the 3′ end.
Activity of the tandem Ets binding sites in the human tie-1 promoter
The tie-1 promoter contains several Ets binding sites (36), including the tandem Ets motifs contained within E-1 and E-2, and mutation of these Ets motifs in the murine tie-1 promoter dramatically reduces its activity in transgenic mice (50). Whereas Ets factors have recently been shown to bind to the E-1 and E-2 Ets sites (51), the relative contribution of these two tandem Ets sites to human tie-1 promoter activity has not been reported. To determine whether the Ets binding motifs in E-1 and E-2 are critical for the regulation of tie-1 and therefore suitable targets for triplex-mediated gene inhibition, we generated 5′ deletions of the human tie-1 promoter by progressive exonuclease-III digestion (Figure 2A) and PCR. The ptie-1luc human tie-1 promoter-driven firefly luciferase reporter constructs were transiently transfected into BAECs, and the activity was measured by dual luciferase assay (36). The progressive 5′ deletion of ptie-1luc beyond the E-2 site demonstrated that this tandem Ets binding site does not affect tie-1 promoter activity in cultured endothelial cells, whereas E-1 lies in the minimal promoter region (Figure 2A). The activity of the E-1 site was further investigated through the introduction of specific mutations into the E-1 Ets motifs of ptie-1luc by overlap PCR (Figure 2B). Mutant E-1 ptie-1luc reporter activity was reduced to 20% (mut-1) and 60% (mut-2) of wild-type ptie-1luc activity, demonstrating that these Ets binding sites are critical for tie-1 regulation (Figure 2C) and highlighting the potential of blocking the E-1 site.
Triplex DNA formation with the human tie-1 promoter
Plasmid binding assays were used as a rapid method to screen for specific triplex DNA formation (46). TFO binding was initially examined against a range of ptie-1luc and human tie-2 promoter (ptie-2luc) luciferase reporter plasmid restriction-fragments (Figure 3A) at a TFO-to-target DNA ratio of ∼1:1 (TFO:DNA duplex). SmaI digestion of ptie-1luc produces a 770-bp fragment that contains the E-1 and E-2 sites (Figure 1). Both the antiparallel oligonucleotides, T1-ap and T2-ap, form triplex DNA on the 770-bp tie-1 promoter fragment following overnight incubation at 37 °C in the presence of 10 mM Mg2+, which promotes purine motif triplex formation/stability (20–22). Figure 3A shows a typical result from these experiments, with triplex DNA formation of radiolabeled T1-ap against a range of restriction-digested tie-1 and tie-2 (ptie-2luc) promoter plasmids. Selectivity of T1-ap and T2-ap for the tie-1 promoter was demonstrated by a lack of triplex DNA formation with irrelevant plasmid DNA fragments, including the human tie-2 promoter (ptie-2luc, Figure 3A), which contains a similar multiple Ets binding site (39,52). No triplex DNA formation was detected with the control parallel G/A oligonucleotides (T1-P and T2-P) under these conditions. To confirm the specificity of T1-ap and T2-ap, they were incubated with SmaI-digested wild-type and E-1 mutant ptie-1luc plasmids (Figure 2B). There was no apparent triplex DNA formation with T1-ap against the ptie-1luc E-1 mutant (mut-1 and mut-2) SmaI fragments, demonstrating its selectivity for the E-1 site (Figure 3B). In contrast, the T2-ap oligonucleotide formed triplex DNA at the wild-type E-2 site present in these ptie-1luc SmaI fragments, as expected (Figure 3C). Similar results were obtained with a partially phosphorothioate-linked T1-ap (PSO-T1-ap), which contains three phosphorothioate bonds at the 3′ end.
High Mg2+ ion concentrations increase the stability of purine motif triplex DNA by decreasing the repulsion between the negatively charged TFO and DNA duplex (21,22). Reducing the Mg2+ ion concentration from 10 mM to ≤ 1 mM strongly decreased the amount of triplex DNA formed by T1-ap and T2-ap TFO in plasmid binding assays (Figure 4E). Physiological levels of monovalent ions generally decrease the formation of DNA triplex with purine motif TFO by promoting self-association (21,22). As expected, increasing concentrations of K+ ions decreased T1-ap and T2-ap triplex DNA formation in the presence of 10 mM Mg2+ (Figure 3D). At physiological potassium ion concentrations (∼150 mM), however, DNA triplex was still detected with T1-ap against the 770-bp SmaI fragment of the tie-1 promoter.
The binding characteristics of TFO were also examined quantitatively by EMSA. Radiolabeled E-1 or E-2 duplex target sites (2 × 10−9 to 10 × 10−9 M) were incubated with increasing concentrations of TFO for 16 to 18 h at 37 °C in binding buffer and separated on 12% nondenaturing polyacrylamide gels. Typical results of experiments with T1-ap are shown in Figure 4. The 27-bp E-1 duplex was shifted to a distinct, more slowly migrating triplex band with increasing concentrations of T1-ap. The relative amount of duplex and triplex DNA was determined from the autoradiographs by scanning densitometry. The concentration of TFO at the midpoint of the titration was taken to be equivalent to the dissociation constant (Kd). Strong triplex DNA formation was observed with both T1-ap and T2-ap, with dissociation constants of 2 × 10−7 to 4 × 10−7 M determined at physiological pH and 37 °C. No triplex DNA formation was observed with the control parallel oligonucleotides (T1-P and T2-P) at concentrations of up to 5 × 10−5 M. The introduction of three phosphorothioate bonds at the 3′ end of TFO (PSOT1-ap) did not significantly affect triplex DNA formation: the Kd of PSOT1-ap was ∼3 × 10−7 M (Figure 4B). With both T1-ap and PSOT1-ap, complete formation of triplex DNA was observed at 1 × 10−6 M in EMSA (Figure 4).
Effect of triplex DNA formation on ptie-1luc luciferase reporter activity in endothelial cells
To determine the effect of targeted triplex formation on the tie-1 promoter, TFO and control oligonucleotides were incubated with ptie-1luc, or the SV40 viral promoter-driven firefly luciferase plasmid pSV40luc as a control, in the presence of 10 mM Mg2+ at 37 °C (16–18 h) to allow the formation of triplex DNA. The entire DNA complex was then transfected into BAECs, and the activity was determined by dual luciferase assay after a 72-h expression period. T1-ap resulted in a concentration-dependent inhibition of up to 60% of ptie-1luc activity at 20 µm in comparison with T1-P-treated controls (Figure 5A). As predicted from our 5′ deletion study of the tie-1 promoter (Figure 2B), T2-ap, which forms strong triplex DNA at E-2, did not affect tie-1 promoter activity (Figure 5A). Tie-1 promoter activity was also not affected by a parallel pyrimidine-rich TFO [T1-(C/T)-P] (see Figure 1) targeted to E-1, which does not form DNA triplex at neutral pH. When T2-ap and T1-ap in combination were preincubated with ptie-1luc, as expected no further inhibition of tie-1 promoter activity was observed (data not shown). The oligonucleotides had no significant effect on the pSV40luc control plasmid activity. It should also be noted that the oligonucleotides did not affect the activity of the cotransfected CMV promoter-driven Renilla luciferase control plasmid (pRL-CMV) used to monitor cell transfection efficiency, even at ≤ 10,000-fold excess.
The replacement of the last three 3′ phosphodiester bonds with phosphorothioate linkages produced oligonucleotides with similar binding characteristics to those of phosphodiester TFO. Preformed PSOT1-ap:E-1 DNA triplex led to a concentration-dependent inhibition of the activity of ptie-1luc of up to 74% at 25 µM in BAECs in comparison with PSOT1-P-treated controls (Figure 5B).
Triplex DNA formation has been investigated as a highly selective means of regulating many clinically relevant targets such as c-myc (25,31), cyclin D1 (24), mdr-1 (27), HIV (28), insulin-like growth factor-1 receptor (29), platelet-derived growth factor (32), rhodopsin (53), and the IgE germline gene promoter (30). In addition to the disruption of transcriptional elongation (21,22,27–29,53), inhibition of gene expression has been achieved through triplex DNA formation at sequences encoding transcription factor binding sites including SP-1, SRF, CNBP, PuF, MAZ, Pax5, PU.1, STAT6, and NF-κB (21,22,24–26,31,32). Here we demonstrate the ability of antiparallel purine motif TFOs to selectively form DNA triplex at two sequences encoding tandem Ets core DNA binding motifs in the tie-1 promoter and the triplex-mediated inhibition of promoter activity through TFO binding to one of these sequences (E-1). Although the inhibition of the IgE germline proximal gene promoter through triplex DNA formation at a sequence regulated by STAT6, NF-κB, and the Ets factor PU.1 was reported recently (30), to our knowledge this is the first demonstration of selective triplex DNA formation at sequences containing multiple Ets binding sites.
Ets transcription factors are key regulators of blood vessel growth (40–45). Tel-1 and Fli-1 have been shown to be essential for yolk-sac angiogenesis and maintenance/integrity of the vasculature beyond embryonic days 11.5 and 12.5, respectively, in transgenic mice (40,41). Ets-1 is upregulated in endothelium in wound healing, inflammation, and the supporting vasculature of tumors, and in cultured endothelial cells following stimulation with the highly potent angiogenic factor, VEGF (43–45). Ets proteins are important regulators of many endothelial-restricted genes including thrombomodulin (54), von Willebrand factor (55), ICAM-2 (56), vascular endothelial (VE)-cadherin (57), and VEGF receptor-1 (Flt-1) (58). The murine tie-1 and tie-2 promoters are transactivated by Ets-1, Ets-2, Elf-1, and Nerf-2 in vitro, and mutation of the Ets binding motifs results in reduced tie-1 promoter activity in mice (50–52). Recently, Elf-1 was shown to bind the tandem Ets motifs contained in the E-1 and E-2 sequences (51); however, the relative contribution of these two sequences to the regulation of the human tie-1 promoter has not been reported. Here we demonstrate that the E-1 Ets binding motifs in the minimal tie-1 promoter are essential for activity in vitro, whereas deletion of the E-2 tandem Ets sites does not affect human tie-1 promoter activity. Moreover, these results are supported by our findings that only TFOs (T1-ap) targeted to E-1 inhibit the activity of the tie-1 promoter in endothelial cells. As similar multiple Ets binding sites are present in several endothelial genes, such as Tie-2 (36,52), thrombomodulin (54), ICAM-2 (56), and VE-cadherin (57), that play key roles in the regulation of endothelial proliferation, differentiation, and function, this approach may have broad applicability to cancer and other pathologies involving endothelial proliferation/dysfunction.
Antiparallel purine motif TFOs were used in this study, as they are generally reported to form triplex DNA with greater stability than unmodified G/T and C/T oligonucleotides (22,53) and do not require low pH (5.0–5.5) to facilitate the protonation of cytosines for triplex DNA formation (21,22). As expected, reduction of Mg2+ ion concentration resulted in a loss of triplex DNA formation/stability. This effect is due to the reported stabilizing effect of divalent cations on DNA triplexes through the neutralization of the repulsive forces between the negatively charged phosphodiester backbones of the TFO and target DNA duplex (21,22,59,60). Conversely, monovalent ions, and in particular K+, are inhibitory to triplex DNA formation/stability with guanine-containing oligonucleotides. This may reflect the ability of monovalent ions to coordinate and stabilize TFO self-association (through G-quartets and related structures) or displace divalent cations and positively charged factors that serve to stabilize DNA triplex (21,60). Physiological levels of K+ ions (∼150 mM) in the presence of 10 mM Mg2+ resulted in a strong decrease of triplex DNA formation.
The destabilizing effect of physiological monovalent ion concentrations may be reduced by the use of oligonucleotide analogs such as N5′ → P3′ phosphoramidates and 2′-aminoethoxy-substituted riboses that result in positively charged TFO (28,30,47).
As phosphodiester oligonucleotides are susceptible to both endo- and exonucleases and subsequently may have a relatively short half-life in cells and tissue culture medium, we attempted to increase TFO stability by using phosphorothioate analogs that are highly resistant to degradation (61). Phosphorothioate oligonucleotides have been reported to produce marked alteration in cellular function in vitro and in vivo (22,31). However, the propensity of phosphorothioates to bind nonnuclear targets means that much of their activity may be due to non-DNA-specific effects, and they may also exhibit reduced triplex DNA formation (21,22,49). Indeed, the replacement of phosphodiester with phosphorothioate bonds resulted in a loss of specificity of PST1-ap for E-1, and binding of the control oligonucleotide (PST1-P) to E-1 was detected at 1 × 10−5 M. Similarly, we found that phosphorothioate-linked TFOs and control oligonucleotides (PST1-ap and PST1-P) nonselectively decreased the relative activity of ptie-1luc and pSV40luc in endothelial cells compared with the activity of the reporter constructs alone (data not shown). However, limiting the number of phosphorothioate linkages to the last three 3′ bases produced oligonucleotides with binding characteristics similar to those of unmodified phosphodiester TFOs and selectively inhibited tie-1 promoter activity in endothelial cells (Figures 3–5). Our results highlight the potential of antigene approaches to specifically modulate the transcriptional activity of genes regulated by Ets transcription factors, and may form the basis of an alternative strategy to inhibit angiogenesis.
Talks KL, Harris AL. (2000) The current status of anti-angiogenic factors. Br. J. Haematol. 109:477–89.
Veikkola T, Karkkainen M, Claesson-Welsh L, Alitalo K. (2000) Regulation of angiogenesis via vascular endothelial growth factor receptors. Cancer Res. 60:203–12.
Lauren J, Gunji Y, Alitalo K. (1998) Is angiopoietin-2 necessary for the initiation of tumor angiogenesis? Am. J. Pathol. 153:1333–9.
Sato TN et al. (1996) Distinct roles of the receptor tyrosine kinases Tie-1 and Tie-2 in blood vessel formation. Nature 376:70–4.
Saharinen P et al. (2005) Multiple angiopoietin recombinant proteins activate the Tie1 receptor tyrosine kinase and promote its interaction with Tie2. J. Cell Biol. 169:239–43.
Marron MB, Hughes DP, Edge MD, Forder CL, Brindle NP. (2000) Evidence for heterotypic interaction between the receptor tyrosine kinases tie-1 and tie-2. J. Biol. Chem. 275:39741–6.
Kontos CD, Cha EH, York JD, Peters KG. (2002) The endothelial receptor tyrosine kinase Tie1 activates phosphatidylinositol 3-kinase and Akt to inhibit apoptosis. Mol. Cell. Biol. 22:1704–13.
Korhonen J et al. (1995) Enhanced expression of the tie receptor tyrosine kinase in endothelial cells during neovascularisation. Blood 86:1828–35.
Kampfer H, Pfeilschifter J, Frank S. (2001) Expressional regulation of angiopoietin-1 and -2 and the tie-1 and -2 receptor tyrosine kinases during cutaneous wound healing: a comparative study of normal and impaired repair. Lab. Invest. 81:361–73.
Kuroda K, Sapadin A, Shoji T, Fleischmajer R, Lebwohl M. (2001) Altered expression of angiopoietins and Tie2 endothelium receptor in psoriasis. J. Invest. Dermatol. 116:713–20.
Uchida T, Nakashima M, Hirota Y, Miyazaki Y, Tsukazaki T, Shindo H. (2000) Immunohistochemical localisation of protein tyrosine kinase receptors Tie-1 and Tie-2 in synovial tissue of rheumatoid arthritis: correlation with angiogenesis and synovial proliferation. Ann. Rheum. Dis. 59:607–14.
Peters KG et al. (1998) Expression of Tie-2/Tek in breast tumor vasculature provides a new marker for evaluation of tumor angiogenesis. Br. J. Cancer 77:51–6.
Stratmann A, Risau W, Plate KH. (1998) Cell type-specific expression of angiopoietin-1 and angiopoietin-2 suggests a role in glioblastoma angiogenesis. Am. J. Pathol. 153:1459–66.
Kaipainen A et al. (1994) Enhanced expression of the Tie receptor tyrosine kinase messenger RNA in the vascular endothelium of metastatic melanomas. Cancer Res. 54:6571–7.
Salven P et al. (1996) Endothelial Tie growth factor receptor provides antigenic marker for assessment of breast cancer angiogenesis. Br. J. Cancer 74:69–72.
Hatva E et al. (1995) Expression of endothelial cell-specific receptor tyrosine kinases and growth factors in human brain tumors. Am. J. Pathol. 146:368–78.
Lin P, Polverini P, Dewhirst M, Shan S, Rao PS, Peters K. (1997) Inhibition of tumor angiogenesis using a soluble receptor establishes a role for Tie2 in pathologic vascular growth. J. Clin. Invest. 100:2072–8.
Lin P et al. (1998) Anti-angiogenic gene therapy targeting the endothelium-specific receptor tyrosine kinase Tie-2. Proc. Natl. Acad. Sci. U. S. A. 95:8829–34.
Moser HE, Dervan PB. (1987) Sequence-specific cleavage of double helical DNA by triple helix formation. Science 238:645–50.
Le Doan T et al. (1987) Sequence-specific recognition, photocrosslinking and cleavage of the DNA double helix by an oligo-α-thymidylate covalently linked to an azidoproflavine derivative. Nucleic Acids Res. 15:7749–60.
Chan PP, Glazer PM. (1997) Triplex DNA: fundamentals, advances, and potential applications for gene therapy. J. Mol. Med. 75:267–82.
Praseuth D, Guieysse AL, Helene C. (1999) Triple helix formation and the anti-gene strategy for sequence-specific control of gene expression. Biochim. Biophys. Acta. 1489:181–206.
Giovannangeli C, Helene C. (2000) Triplex-forming molecules for modulation of DNA information processing. Curr. Opin. Mol. Ther. 2:288–97.
Kim HG, Miller DM. (1998) Anovel triplex-forming oligonucleotide targeted to human cyclin D1 (bcl-1, proto-oncogene) promoter inhibits transcription in HeLa cells. Biochemistry 37:2666–72.
Kim H-G et al. (1998) Inhibition of transcription of the human c-myc proto-oncogene by intermolecular triplex. Biochemistry 37:2299–304.
Neurath MF, Max EE, Strober W. (1995) Pax5 (BSAP) regulates the murine immunoglobulin 3′ alpha enhancer by suppressing binding of NF-alpha P, a protein that controls heavy chain transcription. Proc. Natl. Acad. Sci. U. S. A. 90:3501–5.
Scaggiante B, Morassutti C, Tolazzi G, Michelutti A, Baccarani M, Quadrifogloi F. (1994) Effect of unmodified triple helix-forming oligodeoxyribonucleotide targeted to human multidrug-resistance gene mdr 1 in MDR cancer cells. FEBS Lett. 352:380–4.
Faria M et al. (2001) Targeted inhibition of transcription elongation in cells mediated by triplex-forming oligonucleotides. Proc. Natl. Acad. Sci. U. S. A. 97:3862–7.
Rininsland F, Johnson TR, Chernicky CL, Schulze E, Burfeind P, Ilan J. (1997) Suppression of insulin-like growth factor type I receptor by a triple-helix strategy inhibits IGF-I transcription and tumorigenic potential of rat C6 glioblastoma cells. Proc. Natl. Acad. Sci. U. S. A. 94:5854–9.
Stutz AM, Hoeck J, Natt F, Cuenoud B, Woisetschlager M. (2001) Inhibition of interleukin-4- and CD40-induced IgE germline gene promoter activity by 2′-aminoethoxy-modified triplex-forming oligonucleotides. J. Biol. Chem. 276:11759–65.
McGuffie EM, Pacheco D, Carbone GM, Catapano CV. (2000) Antigene and antiproliferative effects of a c-myc-targeting phosphorothioate triple helix-forming oligonucleotide in human leukemia cells. Cancer Res. 60:3790–9.
Liu J, Xu R, Jin Y, Wang D. (2001) Triplex targeting of human PDGF-B (c-sis, proto-oncogene) promoter specifically inhibits factors binding and PDGF-B transcription. Nucleic Acids Res. 29:783–91.
Ray A, Norden B. (2000) Peptide nucleic acid (PNA): its medical and biotechnical applications and promise for the future. FASEB J. 14:1041–60.
Vasquez KM, Narayanan L, Glazer PM. (2000) Specific mutations induced by triplex-forming oligonucleotides in mice. Science 290:530–3.
White S, Szewczyk JW, Turner JM, Baird EE, Dervan PB. (1998) Recognition of the four Watson-Crick base pairs in the minor groove by synthetic ligands. Nature 391:468–71.
Hewett PW, Daft E, Murray JC. (1998) Cloning and characterization of the tie-2/tek endothelial receptor tyrosine kinase promoter. Biochem. Biophys. Res. Comm. 252:546–51.
Korhonen J et al. (1995) Endothelial-specific gene expression directed by the tie gene promoter in vivo. Blood 86:1828–35.
Laudet V, Hanni C, Stehelin D, Duterque-Coquillaud M. (1999) Molecular phylogeny of the ETS gene family. Oncogene 18:1351–9.
Graves BJ, Petersen JM. (1998) Specificity within the ets family of transcription factors. Adv. Cancer Res. 75:1–55.
Lelievre E, Lionneton F, Soncin F, Vandenbunder B. (2001) The Ets family contains transcriptional activators and repressors involved in angiogenesis. Int. J. Biochem. Cell. Biol. 33:391–407.
Wang LC et al. (1997) Yolk sac angiogenic defect and intra-embryonic apoptosis in mice lacking the Ets-related factor TEL. EMBO J. 16:4374–83.
Hart A et al. (2000) Fli-1 is required for murine vascular and megakaryocytic development and is hemizygously deleted in patients with thrombocytopenia. Immunity. 13:167–77.
Wernert N et al. (1992) c-ets1 proto-oncogene is a transcription factor expressed in endothelial cells during tumor vascularization and other forms of angiogenesis in humans. Am. J. Pathol. 140:119–27.
Wernert N et al. (1994) Stromal expression of c-Ets1 transcription factor correlates with tumor invasion. Cancer Res. 54:5683–5.
Wernert N et al. (2002) The Ets 1 transcription factor is upregulated during inflammatory angiogenesis in rheumatoid arthritis. J. Mol. Med. 80:258–66.
Vasquez KM, Wensel TG, Hogan ME, Wilson JH. (1995) High-affinity triple helix formation by synthetic oligonucleotides at a site within a selectable mammalian gene. Biochemistry 34:7243–51.
Dagle JM, Weeks DL. (1996) Positively charged oligonucleotides overcome potassium-mediated inhibition of triplex DNA formation. Nucleic Acids Res. 24:2143–9.
Beal PA, Dervan PB. (1992) The influence of single base triplet changes on the stability of a pur.pur.pyr triple helix determined by affinity cleaving. Nucleic Acids Res. 20:2773–6.
Cogoi S, Rapozzi V, Quadrifoglio F, Xodo L. (2001) Anti-gene effect in live cells of AG motif triplex-forming oligonucleotides containing an increasing number of phosphorothioate linkages. Biochemistry 40:1135–43.
Iljin K et al. (1999) Role of Ets factors in the activity and endothelial cell specificity of the mouse Tie gene promoter. FASEB J. 13:377–86.
Dube A et al. (2001) Elf-1 is a transcriptional regulator of the Tie2 gene during vascular development. Circ. Res. 88:237–44.
Dube A, Akbarali Y, Sato TN, Libermann TA, Oettgen P. (1999) Role of the Ets transcription factors in the regulation of the vascular-specific Tie2 gene. Circ. Res 84:1177–85.
Perkins BD, Wilson JH, Wensel TG, Vasquez KM. (1998) Triplex targets in the human rhodopsin gene. Biochemistry 37:11315–22.
von der Ahe D et al. (1993) Ets transcription factor binding site is required for positive and TNFα-induced negative promoter regulation. Nucleic Acids Res. 21:5636–43.
Schwachtgen JL et al. (1997) Ets transcription factors bind and transactivate the core promoter of the von Willebrand factor gene. Oncogene 15:3091–102.
McLaughlin F, Ludbrook VJ, Kola I, Campbell CJ, Randi AM. (1999) Characterisation of the tumor necrosis factor (TNF)-alpha response elements in the human ICAM-2 promoter. J. Cell Sci. 112:4695–703.
Gory S, Dalmon J, Prandini MH, Kortulewski T, de Launoit Y, Huber P. (1998) Requirement of a GT box (Sp1 site) and two Ets binding sites for vascular endothelial cadherin gene transcription. J. Biol. Chem. 273:6750–5.
Wakiya K, Begue K, Stehelin D, Shibuya M. (1996) A cAMP response element and an Ets motif are involved in the transcriptional regulation of Flt-1 tyrosine kinase (vascular endothelial growth factor receptor-1) gene. J. Biol. Chem. 271:30823–8.
Blume SW et al. (1999) The integral divalent cation within the intermolecular purine*purine. pyrimidine structure: a variable determinant of the potential for and characteristics of the triple helical association. Nucleic Acids Res. 27:695–702.
Gamper HB Jr., Kutyavin IV, Rhinehart RL, Lokhov SG, Reed MW, Meyer RB. (1997) Modulation of Cm/T, G/A, and G/T triplex stability by conjugate groups in the presence and absence of KCl. Biochemistry 36:14816–26.
Stein CA, Subasinghe C, Shinozuka K, Cohen JS. (1988) Physicochemical properties of phosphorothioate oligodeoxynucleotides. Nucleic Acids Res. 16:3209–21.
We are extremely grateful to Prof. Malcom Stevens, Cancer Research Laboratories, Department of Pharmaceutical Sciences, University of Nottingham, Nottingham, UK, for helpful discussions. This work is supported by the British Heart Foundation and the Birmingham Women’s Hospital NHS Trust.
About this article
Cite this article
Hewett, P.W., Daft, E.L., Laughton, C.A. et al. Selective Inhibition of the Human tie-1 Promoter with Triplex-Forming Oligonucleotides Targeted to Ets Binding Sites. Mol Med 12, 8–16 (2006). https://doi.org/10.2119/2005-00046.Hewett
- Triplex-forming Oligonucleotides (TFO)
- Purine Motif
- Electrophoretic Mobility Shift Assay (EMSA)
- Control Oligonucleotide
- Bovine Aortic Endothelial Cells (BAECs)